###### Strengths and limitations of this study

-   Eighty-nine studies of bevacizumab monotherapy in patients with diverse ophthalmic conditions were included.

-   A majority of relevant existing studies were characterised by small sample sizes, unclear diagnostic criteria and reporting of safety outcomes.

-   The relationship between the incidence of adverse events and variables such as injection techniques, pre-existing risk factors (eg, immunosuppression, cross-contamination) and quality of bevacizumab could not be explored due to limited data.

Introduction {#s1}
============

Age-related macular degeneration (AMD) and diabetic retinopathy (DR) have been identified as two of the three most common causes of age-specific visual impairment in England and Wales.[@R1] More recently, effective treatment options have included anti-vascular endothelial growth factors (anti-VEGFs), which have been shown to both delay deterioration in vision as well as improve vision.[@R2] Ranibizumab (Lucentis, Novartis) is licensed for the treatment of wet AMD and diabetic macular oedema (DMO) and costs £742.17 per injection (0.23 mL vial). Pegaptanib (Macugen; Pfizer) for treatment of AMD is available at a price of £514 per injection (300 μg vial). However, bevacizumab, which cost £242.66 for 4 mL/100 mg vial, is used as an unlicensed intervention in ophthalmic conditions. Although many doses for intravitreal administration can be produced from a single bevacizumab vial and therefore can be supplied for a much lower cost, the actual cost of dispensing smaller doses is uncertain. However, annual cost savings have been estimated if bevacizumab is used as standard treatment instead of ranibizumab in patients with AMD.[@R3]

Bevacizumab remains an unlicensed ophthalmic treatment for a number of reasons. There is an on-going debate with regard to intravitreal bevacizumab (IVB) use and its quality in clinical practice. One major concern relates to the risks associated with the reformulating the drug for intravitreal injections as well as possible adverse events (AEs) associated with systemically administered anti-VEGFs. Bevacizumab is reformulated for intravitreal use to deliver a smaller volume. However, the resulting reformulated product is considered by the Medicines and Healthcare products Regulatory Agency, a UK regulatory body for medicines and medical devices, as an unlicensed product. Another concern has centred predominantly on the possible risk of serious AEs such as endophthalmitis. To date, IVB safety evidence have been inconclusive.[@R4] [@R5] The aim of this review was to assess the safety, in terms of rates of specific serious AEs, of IVB monotherapy in ophthalmic conditions.

Methods {#s2}
=======

We updated an existing systematic review on AEs of intravitreal anti-VEGF reported by van der Reis *et al*,[@R5] which searched reports from 1948 to 2009. We adapted the search strategy by including specific AE terms and omitting selected terms because the previous search strategy: included fewer AE termsused broad terms such as 'cause' and 'response' andapplied specific study design filters, for example, in vitro studies.

Free text and subject headings or thesaurus terms relating to the intervention (eg, bevacizumab, avastin) were combined with AE floating subheadings or specific AE terms. We searched the Cochrane Library; Ovid MEDLINE; MEDLINE in-process; Ovid EMBASE; and Toxicology Literature Online (TOXLINE) from January 2009 to May 2012 because this review was part of a project commissioned by the National Institute for Health and Care Excellence (NICE) through its Decision Support Unit (DSU) between April to August 2012. We did not search clinical trial registers. No experimental and functional study design filter or language restrictions were used. Our MEDLINE search strategy presented as an on-line supplementary file 1 was translated across different databases. Reference lists of all relevant studies and systematic reviews were checked and a citation search of relevant articles was also undertaken.

Study selection {#s2a}
---------------

Study selection was undertaken independently by a minimum of two reviewers using pre-defined criteria. Any disagreements in the selection process were resolved by consensus or referral to a third reviewer. All published or unpublished randomised controlled trials (RCTs), controlled trials or observational studies including ≥10 participants reporting AE data following IVB monotherapy as a primary treatment in patients (aged 18 years or more) with any eye condition were included. Relevant comparators were limited to monotherapies for RCTs only. Articles were excluded if patients had received prior treatment or received IVB as an adjunctive treatment. Non-English reports, narrative reviews, editorials, letters or publications relating to preclinical and biological studies were also excluded.

Data extraction and quality assessment {#s2b}
--------------------------------------

Data extraction and quality assessment were performed independently by one reviewer. Disagreements were resolved by discussion with a second reviewer and if agreement could not be reached, a third reviewer was consulted. Where multiple publications of the same study were identified, data were extracted and reported as a single study. Information abstracted included study characteristics, participant details (eg, number of patients, eye condition, mean age and baseline comparability), intervention and comparator details (eg, source, dose, injection quality and frequency of treatment) and outcomes. Outcomes of interest were limited to important and serious ocular and systemic AEs as listed below:

Systemic AEs DeathHospitalisationNon ocular haemorrhage (gastrointestinal, pulmonary, other non-ocular bleeds)Arterial thromboembolismHypertensionMyocardial infarctionCerebrovascular accident (stroke)Transient ischaemic attack

Ocular AEs Infectious endophthalmitis (infection of the eye)Retinal detachmentRetinal (pigment epithelium) tearAnterior chamber reaction (including acute intraocular inflammation; uveitis; inflammation of the anterior chamber and hypopyon)Ocular haemorrhageLens damage/injury (including cataract, clouding of the lens)Ocular hypertension (raised intraocular pressure \>21 mm Hg)Visual loss

For RCTs, study quality was assessed in accordance to the Cochrane Risk of Bias Tool. Additionally, we assessed items relating to safety data for RCTs; these included follow-up period greater than 6 months, definition of AE and description of method of ascertaining AE. A formal quality assessment was not undertaken for observational studies. While checklists exist for evaluating the methodological quality of a range of non-randomised studies, there is no consensus on how to incorporate a single tool to appraise different study types in a review.[@R6] It was anticipated that a variety of non-randomised study designs would be identified, so criteria assessed were limited to study design (eg, prospective or retrospective), length of follow-up and baseline comparability when appropriate.

Data analysis {#s2c}
-------------

A pooled analysis was undertaken using the Cochrane Review Manager software where appropriate. The relative risk was calculated for dichotomous outcomes using a fixed effects model (Mantel-Haenszel method). Otherwise, descriptive statistics were tabulated. Estimates of AE rates were calculated by dividing the number of events by the number of patients who received IVB (event rate per patient) or the number of eyes treated (event rate per treated eye).

Results {#s3}
=======

A flow chart of the study selection is shown in [figure 1](#BMJOPEN2014005244F1){ref-type="fig"}. Eighty-nine full text articles were included (n=22 RCTs, n=67 non-randomised studies). Of these 20 studies, including 1 RCT, were identified from the previous review. A total of 293 full text articles were excluded. Reasons for exclusion were wrong population, intervention or study type (n=162), unsuitable publication type (reviews, commentaries or editorials; n=34) and absence of usable data (n=97). A full list of excluded studies with reasons for exclusion is available on request.

![Summary of study selection. This flow chart outlines the process of study selection for the systemic review based on the recommendations of the PRISMA statement. RCT, randomised controlled trial.](bmjopen2014005244f01){#BMJOPEN2014005244F1}

Identified studies {#s3a}
------------------

A total of 22 RCTs comparing IVB with a variety of interventions as well as an observational control group with safety data were included, as presented in [table 1](#BMJOPEN2014005244TB1){ref-type="table"}.[@R2] [@R7] Study populations were patients with AMD (n=7 studies); DMO (n=8 studies); retinal vein occlusion (RVO) (n=4 studies) and other ophthalmic conditions (n=3). Assessment of study quality is presented as an on-line supplementary file 2. Study quality was considered to be moderate to low with only two RCTs[@R16] [@R19] meeting the criteria for valid safety data.

###### 

Summary of included randomised controlled studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study identifier,\                                                                 Description of study population                                                                           Number of patients (eyes)   Interventions (treatment schedule and numbers treated)                                                                                                   Comparators (treatment schedule and numbers treated)                                                    Reported safety outcomes                                                                                                Information relating to preparation of intravitreal bevacizumab
  study location                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  ---------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  *Studies including patients with age-related macular degeneration (n=7 studies)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Bashshur *et al*,[@R14]\                                                           Neovascular age-related macular degeneration\                                                             62 (NR)                     IVB: 2.5 mg, mean 2.4 injections (n=32)                                                                                                                  Laser therapy: mean 2.3 sessions (n=30)                                                                 Systemic adverse events\                                                                                                IVB prepared in hospital pharmacy
  Lebanon                                                                            BCVA, 20/50 to 20/200\                                                                                                                                                                                                                                                                                                                                                                                 Hypertension\                                                                                                           
                                                                                     Submacular scarring or haemorrhage, sparing the fovea\                                                                                                                                                                                                                                                                                                                                                 Outcomes at 6 months                                                                                                    
                                                                                     Mean age, 74.5 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Biswas *et al*,[@R15] India                                                        Choroidal neovascularisation secondary to age-related macular degeneration\                               60 (60)                     IVB: 1.25 mg, 3 monthly injections, mean 4.3 (n=30)                                                                                                      IVR: 0.5 mg, 3 monthly injections, mean 5.6 (n=30)                                                      Significant adverse events (unspecified)\                                                                               Methods of IVB preparation not reported
                                                                                     BCVA, 35 to 70 ETDRS letter\                                                                                                                                                                                                                                                                                                                                                                           Outcome at 18 months                                                                                                    
                                                                                     CMT, \>250μm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                     Mean age, not reported                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CATT 2012,[@R16] USA                                                               Choroidal neovascularisation secondary to age-related macular degeneration\                               1185 (1107)                 IVB: 1.25 mg, monthly or as needed (n=586)                                                                                                               IVR: 0.5 mg, monthly or as needed (n=599)                                                               Death\                                                                                                                  Re-packaging of commercially available bevacizumab into glass vials in an aseptic facility
                                                                                     BCVA, 20/25 to 20/320\                                                                                                                                                                                                                                                                                                                                                                                 Endophthalmitis\                                                                                                        
                                                                                     Mean age, 79.5 years                                                                                                                                                                                                                                                                                                                                                                                   Hypertension\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Adverse events associated with anti-VEGF treatment\                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Arteriothrombotic adverse events\                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 2 years                                                                                                     

  IVAN 2012,[@R19] UK                                                                Neovascular age-related macular degeneration;\                                                            610                         IVB, 1.25 mg as continuous or as needed treatment at 3 separate visits (n=296)                                                                           IVR, 0.5 mg as continuous or as needed treatment at 3 separate visits (n=314 eyes)                      Serious adverse events\                                                                                                 Commercially repackaged and prefilled syringes IVB
                                                                                     BCVA, ≥25 ETDRS letters\                                                                                                                                                                                                                                                                                                                                                                               Death\                                                                                                                  
                                                                                     Mean age, 77.0 years                                                                                                                                                                                                                                                                                                                                                                                   Arteriothrombotic events\                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Transient ischaemic attack\                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Hospitalised for angina\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 1 year                                                                                                      

  Lazic and Gabric,[@R20] Croatia                                                    Minimally classic or occult choroidal neovascularisation secondary to age-related macular degeneration\   165 (165)                   IVB, 1.25 mg (n=55)                                                                                                                                      1\. Laser therapy: according to recommended standard procedures (n=55)\                                 Pigment epithelial tears\                                                                                               Methods of IVB preparation not reported
                                                                                     BCVA, ≥20/400\                                                                                                                                                                                                                                                                                 2. Combination treatment, that is, laser therapy followed by IVB, 1.25 mg within an hour (n=55)         Posterior vitreous detachment\                                                                                          
                                                                                     Mean age, 75.7 years                                                                                                                                                                                                                                                                                                                                                                                   Thromboembolic events\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cataract progression\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 3 months                                                                                                    

  Schimid-Kubista *et al*,[@R24] Austria                                             Choroidal neovascularisation secondary to neovascular age-related macular degeneration\                   48 (48)                     IVB, 1.0 mg every 6 weeks; total of 3 injections (n=13)                                                                                                  1\. IVP, 0.3 mg every 6 weeks; total of 3 injections (n=18)\                                            IOP\                                                                                                                    Methods of IVB preparation not reported
                                                                                     BCVA, 5 to 40 ETDRS letters\                                                                                                                                                                                                                                                                   2. IVB, 1.0 mg then two injections of IVP 0.3 mg 6 weeks apart (n=17)                                   Raised blood pressure\                                                                                                  
                                                                                     Mean age, 77.5 years                                                                                                                                                                                                                                                                                                                                                                                   Outcomes at 6 months                                                                                                    

  Tufail *et al*,[@R26] UK                                                           Neovascular age-related macular degeneration;\                                                            131 (NR)                    IVB, 1.25 mg, three loading injections at 6 week intervals followed by further treatment if required at 6 week intervals, mean injections 7.1 (n=65).\   1\. Laser therapy, (n=16)\                                                                              Endophthalmitis\                                                                                                        IVB injections were prepared as single use syringes with a shelf life of 6 weeks. Syringes were placed in sealed plastic pouches
                                                                                     BCVA, 6/12 to 6/96 (Snellen\                                                                                                          \                                                                                                                                                        2. IVP, 0.3 mg, (n=38)\                                                                                 Uveitis\                                                                                                                
                                                                                     equivalent) or 25 to 70 ETDRS letter scores\                                                                                                                                                                                                                                                   3. Sham injection, (n=12)                                                                               Retinal detachment\                                                                                                     
                                                                                     Mean age, 81 years                                                                                                                                                                                                                                                                                                                                                                                     Retinal tear\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Vitreous haemorrhage\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Lens damage\                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Myocardial infarction\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Stroke\                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cerebral infarction\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Death\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 1 year                                                                                                      

  *Studies including patients with diabetic macular oedema (n=8 studies)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Ahmadieh *et al*,[@R7] Iran                                                        Diabetic macular oedema\                                                                                  101 (115)                   IVB, 1.25 mg at baseline and weeks 6 and 12 (n=41 eyes)                                                                                                  1\. IVB, 1.25 mg and IVT, 2 mg at baseline, then IVB, 1.25 mg at weeks 6 and 12 (n=37 eyes)\            Death\                                                                                                                  Methods of IVB preparation not reported
                                                                                     BCVA,≤20/40\                                                                                                                                                                                                                                                                                   2. Sham injection (n=37 eyes)                                                                           Marked anterior chamber reaction\                                                                                       
                                                                                     Mean age, 59.7 years                                                                                                                                                                                                                                                                                                                                                                                   Progression of fibrous proliferation\                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 24 weeks                                                                                                    

  DRCRN 2007,[@R10] USA                                                              Diabetic macular oedema (patients with type 1 and type 2 diabetes)\                                       109 (109)                   1\. IVB, 1.25 mg at baseline\                                                                                                                            1\. Laser treatment at baseline (n=19 eyes)\                                                            Endophthalmitis, raised intraocular pressure, raised blood pressure, myocardial infarction, congestive heart failure\   Methods of IVB preparation not reported
                                                                                     BCVA, ETDRS VA letter score, 24 to78 (20/32 to 20/320)\                                                                               and week 6\                                                                                                                                              2. IVB, 1.25 mg at baseline, laser treatment at week 3, then IVB, 1.25 mg at week 6 (n=22 eyes)\        Outcomes over a 70-week period                                                                                          
                                                                                     CMT ≥275 μm\                                                                                                                          (n=22 eyes)\                                                                                                                                             3. IVB, 1.25 mg at baseline, sham at week 6 (n=22 eyes)                                                                                                                                                                         
                                                                                     Median age, 65 years                                                                                                                  2. IVB, 2.5 mg at baseline, week 6 (n=24 eyes)                                                                                                                                                                                                                                                                                                                                           

  Faghihi *et al*,[@R11] Iran                                                        Diabetic macular oedema (patients with type 2 diabetes)\                                                  110 (130)                   IVB, 1.25 mg, dosing schedule not reported (n = 42 eyes)                                                                                                 1\. Laser (n = 47 eyes)\                                                                                Safety assessment\                                                                                                      Methods of IVB preparation not reported
                                                                                     BCVA, ≤20/40\                                                                                                                                                                                                                                                                                  2. IVB (1.25 mg) + IVT (2 mg) (n=41 eyes)                                                               Vitreous haemorrhage\                                                                                                   
                                                                                     CMT, \>250μm\                                                                                                                                                                                                                                                                                                                                                                                          Ocular hypertension (≥23 mm Hg)\                                                                                        
                                                                                     Mean age, 57.5 years                                                                                                                                                                                                                                                                                                                                                                                   Outcome 16 weeks                                                                                                        

  Lim *et al*,[@R21] Korea                                                           Diabetic macular oedema\                                                                                  111 (120)                   IVB, 1.25 mg at baseline and at week 6 (n=36)                                                                                                            1\. IVT, 2 mg (n=38)\                                                                                   Hypertension\                                                                                                           Methods of IVB preparation not reported
                                                                                     BCVA, not reported\                                                                                                                                                                                                                                                                            2. IVB (1.25 mg)+IVT (2 mg) (n=37)                                                                      Thromboembolic AE\                                                                                                      
                                                                                     CMT ≥300 µm\                                                                                                                                                                                                                                                                                                                                                                                           Serious ocular complications\                                                                                           
                                                                                     Mean age, 60.0 years                                                                                                                                                                                                                                                                                                                                                                                   IOP\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 1 year                                                                                                      

  Marey and Ellakwa,[@R22] Egypt                                                     Clinically significant diabetic macular oedema\                                                           90 (90)                     IVB, 1.25 mg (n=30)                                                                                                                                      1\. IVT, 4 mg (n=30)\                                                                                   IOP\>22 mm Hg\                                                                                                          Methods of IVB preparation not reported
                                                                                     BCVA, not reported\                                                                                                                                                                                                                                                                            2. IVB (1.25 mg)+IVT (4 mg) (n=30)                                                                      Cataracts\                                                                                                              
                                                                                     CMT at baseline, reported per study groups\                                                                                                                                                                                                                                                                                                                                                            Outcomes at 12 weeks                                                                                                    
                                                                                     Mean age, 57.7 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Michaelides *et al*,[@R9] UK                                                       Clinically significant diabetic macular oedema (in patients with type 1 or type 2 diabetes)\              80 (80)\                    IVB, 1.25 mg at baseline, and then every 6 weeks as needed; number of injections ranged between 3 and 9 (n=42)                                           Laser therapy, every 4 months as needed; number of treatments, ranged between 1 and 4 (n=38)            Death\                                                                                                                  IVB prepared by Moorfields, London
                                                                                     BCVA, 35 to 69 ETDRS letters\                                                                             \                                                                                                                                                                                                                                                                                            IOP\                                                                                                                    
                                                                                     CMT ≥279µm\                                                                                               \                                                                                                                                                                                                                                                                                            Loss of 30 ETDRS letters\                                                                                               
                                                                                     Mean age, 64.2 years                                                                                                                                                                                                                                                                                                                                                                                   Vitreous haemorrhage\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Cerebrovascular accident\                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 12 months                                                                                                   

  Shahin *et al*,[@R25] Egypt                                                        Diffuse diabetic macular oedema\                                                                          32 (48)                     IVB, 1.25 mg, single injection (n=24 eyes)                                                                                                               IVT, 4 mg, single injection (n=24 eyes)                                                                 IOP (≥23--43 mm Hg)\                                                                                                    Methods of IVB preparation not reported
                                                                                     BCVA, not reported\                                                                                                                                                                                                                                                                                                                                                                                    Visually significant cataract\                                                                                          
                                                                                     CMT ≥292µm\                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 3 months                                                                                                    
                                                                                     Mean age, 52.7 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Soheilian *et al*,[@R2] Iran                                                       Diabetic macular oedema\                                                                                  129 (150)                   IVB, 1.25 mg at baseline; treated repeated at 3 monthly interval on an as-needed basis (n=50 eyes)                                                       1\. IVB, 1.25 mg+IVT, 2 mg; treated repeated at 3 monthly interval on an as-needed basis (n=50 eyes)\   Death\                                                                                                                  Methods of IVB preparation not reported
                                                                                     BCVA, 20/40 to 20/300\                                                                                                                                                                                                                                                                         2. Laser therapy; treated repeated at 3 monthly interval on an as-needed basis (n=50 eyes)              Lens opacities\                                                                                                         
                                                                                     CMT, not used as inclusion criterion\                                                                                                                                                                                                                                                                                                                                                                  IOP\                                                                                                                    
                                                                                     Mean age, 60.5 years                                                                                                                                                                                                                                                                                                                                                                                   Vitreous haemorrhage\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            High risk proliferative diabetic retinopathy\                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 2 years\                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            \                                                                                                                       

  *Studies including patients with retinal vein occlusion (n=4 studies)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Cekic *et al*,[@R8] Turkey                                                         Macular oedema due to branch retinal vein occlusion\                                                      21 (21)\*                   IVB: 1.25 mg, mean 1.6 injections\                                                                                                                       IVT: 4 mg, mean 1.4 injections (n=17)\                                                                  Endophthalmitis, uveitis, thromboembolic events\                                                                        Methods of IVB preparation not reported
                                                                                     BCVA, ≤20/40\                                                                                                                         (n=14)                                                                                                                                                   IVT+IVB (n=21)                                                                                          Outcomes at 6 months                                                                                                    
                                                                                     CMT, \>250 μm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                     Mean age, 63 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ding *et al*,[@R17] China                                                          Macular oedema secondary to retinal vein occlusion (unspecified)\                                         31 (32)                     IVB, 1.25 mg, repeat treatment given if condition persisted or recurred (n=16 eyes)                                                                      IVT, 4 mg, repeat treatment given if condition persisted or recurred (n=16 eyes)                        IOP\>21 mm Hg\                                                                                                          Methods of IVB preparation not reported
                                                                                     BCVA, ≤20/40\                                                                                                                                                                                                                                                                                                                                                                                          Outcomes at 9 months                                                                                                    
                                                                                     CMT, \>250 μm\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                     Mean age, 54 years                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Epstein *et al*,[@R12] Sweden                                                      Macular oedema secondary to central retinal vein occlusion\                                               60 (60)                     IVB, 1.25 mg at baseline and at weeks 6, 12 and 18 (n =30)                                                                                               Sham injection: at baseline and at weeks 6, 12 and 18 (n=30)                                            Endophthalmitis\                                                                                                        IVB prepared in hospital pharmacy
                                                                                     BCVA, 15 to 65 ETDRS letters (approx. 20/50 to 20/500)\                                                                                                                                                                                                                                                                                                                                                Retinal tear\                                                                                                           
                                                                                     CMT ≥ 300μm                                                                                                                                                                                                                                                                                                                                                                                            Retinal detachment\                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            No serious non-ocular adverse events\                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 6 months                                                                                                    

  Moradian *et al*,[@R13] Iran                                                       Acute branch retinal vein occlusion\                                                                      81 (81)                     IVB, 1.25 mg at baseline and 6 weeks (n=42)                                                                                                              Sham injection, at baseline and 6 weeks (n=39)                                                          Foveal haemorrhage\                                                                                                     Methods of IVB preparation not reported
                                                                                     BCVA, ≤20/50\                                                                                                                                                                                                                                                                                                                                                                                          Foveal ischemia\                                                                                                        
                                                                                     Mean age, 57.6 years                                                                                                                                                                                                                                                                                                                                                                                   Outcomes at 12 weeks                                                                                                    

  *Studies including patients with other ophthalmic conditions (n=3 studies)*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Gharbiya *et al*,[@R18] Italy                                                      Pathologic myopia†\                                                                                       32 (32)                     IVB, 1.25 mg at baseline, then given as needed\                                                                                                          IVR, 0.5 mg at baseline, then given as needed (n=16 eyes)                                               Systemic adverse events\                                                                                                Methods of IVB preparation not reported
                                                                                     BCVA, ≥26 ETDRS letters\                                                                                                              (n=16 eyes)                                                                                                                                                                                                                                                      Endophthalmitis Retinal detachment\                                                                                     
                                                                                     Mean age, 59.5 years                                                                                                                                                                                                                                                                                                                                                                                   Vitreous haemorrhage\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Hypertension\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            IOP\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Outcomes at 6 months                                                                                                    

  Patwardhan *et al*,[@R23] India                                                    Vitreous haemorrhage (grade 3 or 4), secondary to Earl\'s disease\                                        20 (20)                     IVB, 1.25 mg every 4 weeks (n=10 eyes)                                                                                                                   No active treatment (n=10 eyes)                                                                         Tractional retinal detachment\                                                                                          Methods of IVB preparation not reported
                                                                                     Mean age, 25.5 years                                                                                                                                                                                                                                                                                                                                                                                   Outcomes at 12 weeks                                                                                                    

  Yazdani *et al*,[@R27] Iran                                                        Neovascular glaucoma\                                                                                     26 (26)                     IVB, 2.5 mg; 3 injections given monthly (n=14 eyes)                                                                                                      Sham injection; 3 injections given monthly (n=12 eyes)                                                  Hyphema\                                                                                                                Methods of IVB preparation not reported
                                                                                     BCVA ≥20/200\                                                                                                                                                                                                                                                                                                                                                                                          Injection related adverse events\                                                                                       
                                                                                     Mean age, 59.5 years                                                                                                                                                                                                                                                                                                                                                                                   Outcomes at 6 months                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This table summarises the study characteristics of the 22 included randomised controlled studies. Data shown here include patient charateristics, interventions and outcomes reported in the included studies.

Calculation of mean age, when not specified, was based on the assumption that reported ages per treatment arms were normally distributed.

\*The study population included 52 patients, of these 21 patients received a combination of intravitreal bevacizumab and intravitreal triamcinolone.

†This condition was defined as an axial length of at least 26.5 of subfoveal or juxtafoveal choroidal neovascularisation.

BCVA, best corrected visual acuity; CMT, central macular thickness; ETDRS, Early Treatment Diabetic Retinopathy Score; IOP, intraocular pressure; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptinib; IVR, intravitreal ranibizumab.

Sixty-seven observational studies were included as summarised in [table 2](#BMJOPEN2014005244TB2){ref-type="table"}. Most studies included patients with a single condition with fewer studies including a population with multiple conditions. Study quality was, generally, difficult to assess due to the quality of reporting. Approximately 65% of studies (n=44/67) were retrospective in design with follow-up periods of more than 6 months reported in less than a third (n=18/67) of included studies. Baseline characteristics of participants were comparable in two non-randomised studies[@R28] [@R29] and three case-control studies.[@R30]

###### 

Summary of included observational studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                    Study type                                                                           Condition (patients\' mean age in years)                                   Number of patients (number of eyes)                                 Baseline comparability (yes/ no/unknown/not applicable)   Dosage (mg) including frequency of dosing                                                                                                               Number of injections/patients (mean)                                    Follow-up                                                  Information on preparation of bevacizumab   Funding                                                                                                                               Notes
  -------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------- ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abraham-Marin (2007)[@R33]       Case series, (prospective)                                                           CNV due to AMD (76)                                                        39 (39)                                                             NA                                                        2.5 mg                                                                                                                                                  1                                                                       4 weeks                                                    NR                                          NR                                                                                                                                    

  Arevalo (2010)[@R34]             Case series, (retrospective)                                                         CNV due to AMD                                                             180 (207)                                                           NA                                                        1.25 mg (59.9%)\                                                                                                                                        5.1 (per eye)                                                           1, 3, 6, 12 and 24 months after the initial injection      NR                                          Arevalo-Coutinho Foundation for Research in Ophthalmology, Venezuela                                                                  
                                                                                                                                                                                                                                                                                                                                 2.5 mg (40.1%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                 Frequency of dosing at discretion of treating physician                                                                                                                                                                                                                                                                                                                                                                                                                      

  Artunay (2009)[@R35]             Case series, (retrospective)                                                         Various\* (NR)                                                             NR (1822)                                                           NA                                                        1.25 mg once or repeated                                                                                                                                NR                                                                      1--7 days, 4 weeks, 8 weeks                                NR                                          NR                                                                                                                                    

  Azad (2008)[@R36]                Non-randomised trial (prospective)                                                   subfoveal CNV due to AMD (63)                                              40 (40)                                                             NA                                                        1.25 mg                                                                                                                                                 2.4                                                                     6 months                                                   NR                                          NR                                                                                                                                    

  Baba (2010)[@R37]                Case series (retrospective)                                                          Myopic CNV                                                                 40 (40)                                                             Yes                                                       1.25 mg                                                                                                                                                 1.3 to 1.5                                                              24 months                                                  NR                                          NR                                                                                                                                    Treatment groups: PDT (n=16); PDT and IVB (n=12); IVB only (n=12)

  Bakri (2009)[@R38]               Case series, (retrospective)                                                         Various† (NR)                                                              35 (70)                                                             NA                                                        1.25 mg                                                                                                                                                 5.9                                                                     39 days                                                    NR                                          The Research To Prevent Blindness, New York                                                                                           

  Bashshur (2009)[@R28]            Nonrandomised trial, open-label, prospective (extension study)                       CNV due to AMD (72.2)                                                      51 (51)                                                             NA                                                        2.5 mg                                                                                                                                                  2.5 (3.4 during first 12 months, decreased to 1.5 during second year)   24 months                                                  local dispensing service                    American University of Beirut Medical Center                                                                                          

  Carneiro (2010)[@R39]            Cohort, (prospective)                                                                Subfoveal or juxtafoveal CNV secondary to AMD (76.9)                       \(80\)                                                              NR                                                        1.25 mg                                                                                                                                                 4                                                                       6 months, 12 months                                        NR                                          Sociedade Portuguesa de Oftalmologia, Hospitalde Sao Joao,                                                                            

  Carneiro (2011)[@R40]            Cohort (retrospective):IVB vs IVR                                                    AMD (77.8)                                                                 97 (IVB group)                                                      Yes (IVB:IVR)                                             1.25 mg;                                                                                                                                                7.8                                                                     2.3 years                                                  NR                                          Sociedade Portuguesa de Oftalmologia, Hospitalde Sao Joao, Swiss National Foundation and Walter and Gertrud Sienenthaler Foundation   Increased rate of ATEs in IVB group compared to IVT (secondary analyses

  Chen (2010)[@R41]                Non-randomised cohort (retrospective)                                                MO due to BRVO (60.7)                                                      24 (25)                                                             Yes (IVB:IVT:control; n=83)                               2.5 mg single injection then as needed                                                                                                                  NR                                                                      10 months (mean)                                           NR                                          NR                                                                                                                                    Patients received IOP-lowering treatment during follow-up period if IOP ≥21 mm Hg.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Anterior paracentesis was performed before IVB to reduce ocular pressure.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Author\'s conclusion:\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              IVB better than IVT

  Cleary (2008)[@R42]              Case series (retrospective)                                                          Neovascular AMD (75)                                                       111 (112)                                                           NA                                                        1.25 mg, once then as needed                                                                                                                            NR                                                                      4.9 (range 1--12)                                          Local dispensing service                    None                                                                                                                                  

  Costa (2006)[@R43]               Non-randomised dose escalation study (prospective)                                   CNV caused by AMD (74.6)                                                   45 (45)                                                             Yes (1.0 mg:1.5 mg:2.0 mg)                                1.0 mg, 1.5 mg and 2.0 mg                                                                                                                               NR                                                                      3                                                          Local dispensing service                    Public funding (Foundation for Research Support of the State of São Paulo)                                                            Reported as a dose escalation study but difficult to tell how many doses each participant was given and how far apart

  Costagliola (2009)[@R44]         Case series (retrospective)                                                          CNV (subfoveal) due to AMD (73.2)                                          68 (68)                                                             NA                                                        1.25; then monthly as per needed                                                                                                                        3.87 (first 6 months); 1.09 (for remaining 6 months)                    12                                                         Local dispensing service                    NR                                                                                                                                    Exclusion criteria included previous history of thromboembolic events; uncontrolled hypertension, BP \>150/90 mm Hg.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Topical antibiotics prescribed for 3 days, after injection

  Curtis (2010)[@R45]              Cohort (retrospective)                                                               AMD (median, 81.0)                                                         27 962 (IVB only; n=146 942)                                        Yes (IVB:PDT: IVP:IVR)                                    NR                                                                                                                                                      NR                                                                      12 months                                                  NR                                          Research agreement between OSI Eyetech and Duke University                                                                            Patient data were censored when at the time when a treatment which was different from initially assigned intervention was received. Between July and December 2006, study population was limited to treatment-naïve patients who received bevacizumab or ranibizumab

  Falkenstein (2007)[@R46]         Case series (prospective)                                                            AMD (79.4)                                                                 70 (NR)                                                             NA                                                        1.25 mg assumed (0.05 mL)                                                                                                                               1.74 (calculated from 122 injections for 70 patients)                   3,10 and 15 minutes                                        NR                                          NR                                                                                                                                    

  Fintak (2008)[@R47]              cohort (retrospective)                                                               Various (NR)                                                               12 585 (IVB injections)                                             NR                                                        1.25 mg                                                                                                                                                 NR                                                                      5 days                                                     Local dispensing service                    NR                                                                                                                                    Number of injections not reported

  Fong (2008)[@R48]                Case series (retrospective)                                                          AMD (82)                                                                   109 (109)                                                           NA                                                        1.25 mg, three consecutive monthly injections then as needed                                                                                            NR                                                                      9.4 months (range 6-12)                                    Compounding pharmacy                        NR                                                                                                                                    

  Frenkel 2010[@R49]               Cohort (retrospective)                                                               AMD (80)                                                                   47‡                                                                 Unknown (IVB: ranibizumab: pegaptanib)                    1.25 mg                                                                                                                                                 1                                                                       20 minutes                                                 NR                                          NR                                                                                                                                    First injection only selected for the study

  Fukami (2011)[@R50] (abstract)   Case series (retrospective)                                                          NR (NR)                                                                    12 (12)                                                             NA                                                        NR                                                                                                                                                      NR                                                                      2 days                                                     NR                                          NR                                                                                                                                    

  Gamulescu (2010)[@R51]           Cohort (retrospective)§                                                              AMD (77.5)                                                                 30 (NR)                                                             NR                                                        1.25 mg every 4 weeks\                                                                                                                                  NR                                                                      2-4 months after last injection                            NR                                          NR                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                 3 initial injections                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Gomi (2008)[@R52]                Case series (Retrospective)                                                          Polypoidal choroidal vasculopathy (65.4)                                   11 (11)                                                             NA                                                        1 mg¶ once or as needed\                                                                                                                                NR                                                                      9.4 months (±4.4)                                          NR                                          NR                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                 \                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Good (2011)[@R31]                Cohort (retrospective)\*\*                                                           AMD (76.6)                                                                 NR (101)††                                                          Yes                                                       1.25 mg                                                                                                                                                 7.0                                                                     86.6 days mean                                             NR                                          NR                                                                                                                                    

  Goverdhan (2008)[@R53]           Case series (retrospective)                                                          CNV due to AMD (79.5)                                                      53 (53)                                                             NA                                                        1.25 mg\                                                                                                                                                1.36                                                                    Day 1 and after 2 week visits then at 4-week intervals.\   NR                                          NR                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                 Repeat injections offered if CNV persisted or fresh haemorrhage or subretinal fluid observed.                                                                                                                                   Minimum 6 months (range 4 to 12 months)                                                                                                                                                                                                      

  Gower (2011)[@R54] (abstract)    Cohort (retrospective)                                                               Neovascular AMD (NR)                                                       NR (NR)                                                             NR (IVB:IVR)                                              NR                                                                                                                                                      NR                                                                      NR                                                         NR                                          NR                                                                                                                                    HRs adjusted for baseline comorbidities, demographics and socio-economic status

  Hernandez-Rojas (2007)[@R55]     Case series (prospective)                                                            CNV due to pathological myopia (53.9)                                      13 (13) (at follow-up---one patients lost to follow-up)             NA                                                        2.5 mg/0.1 mL once or as needed                                                                                                                         NR                                                                      3 months                                                   NR                                          NR                                                                                                                                    

  Higashide (2012)[@R56]           Case series (retrospective)                                                          Neovascular glaucoma (63.5)                                                70 (84)                                                             NA                                                        1.25 mg                                                                                                                                                 1.4                                                                     3 months                                                   NR                                          NR                                                                                                                                    

  Hollands (2007)[@R57]            Case series (prospective)                                                            Neovascular AMD (84.6%); DMO (6.7%); Others---histoplasmosis (8.7%) (76)   104                                                                 NA                                                        1.25 mg\                                                                                                                                                NR                                                                      30 min                                                     NR                                          NR                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                 \                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Ikuno (2009)[@R58]               Case series (retrospective)                                                          CNV due to myopia (58.4)                                                   63 (63)                                                             NA                                                        1 mg                                                                                                                                                    2.4                                                                     12 months                                                  NR                                          The Ministry of Education, Culture, Sports Science and Technology of Japan;\                                                          Re-injection considered after 2--3 months if fluorescein leakage in angiograam or subretinal fluid persisted
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Health and Labor Sciences Research of Japan                                                                                           

  Inman (2011)[@R59]               Case series (retrospective)                                                          NR                                                                         608 (sample included patients that received IVB, IVP and IVR)       NA                                                        NR                                                                                                                                                      Unclear (1841 injections of IVB, 428 IVP and 2421 IVR)                  4.4 years                                                  Local dispensing service                    NR                                                                                                                                    This study reported incidence of infectious endophthalmitis associated with 2% topical lidocaine gel anaesthesia. No information on conditions being treated or patient demographics.

  Jaissle (2009)[@R60]             Case series (prospective)                                                            MO due to BRVO (median, 68)                                                23 (23)                                                             NA                                                        1.25 mg (re-injection considered if macular oedema persisted in foveal area and visual acuity 20/32 or worse)                                           NR                                                                      1 year. (examined every 6 weeks)                           NR                                          German Opthalmological Society                                                                                                        During the 1-year\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              follow-up, an average of 2.4 re-injections (range, 0--5) were administered, with a mean of 1.6 re-injections within the first 6 months (weeks 6--24) and a further 0.8 re-injections over the latter 6 months (weeks 30--48).

  Johnson (2010)[@R61]             Case series (retrospective)                                                          Various‡‡ (76.5)                                                           173 (193)                                                           NA                                                        NR                                                                                                                                                      3.98                                                                    Median follow-up; 40 days (range 19 to 170 days)           NR                                          Queen\'s University, Canada                                                                                                           

  Jonas (2007)[@R62]               Case series (retrospective)                                                          AMD                                                                        625 (684)                                                           NA                                                        1.5 mg                                                                                                                                                  1.95                                                                    ≥4 weeks                                                   Local dispensing service                    NR                                                                                                                                    534 re-injections

  Jonas (2008)[@R63]               Case series (retrospective, consecutive)                                             Various                                                                    NR (3818 IVB injections)                                            NA                                                        1.5 mg                                                                                                                                                  NR                                                                      ≥3 months                                                  NR                                          None                                                                                                                                  

  Julian (2011)[@R64]              Case series (retrospective)                                                          CNV due to uveitis (median, 41.9)                                          15 (15)                                                             NA                                                        1.25 mg (re-treatment based on signs of active neovascularisation)                                                                                      4.25                                                                    17.6 (median)                                              NR                                          NR                                                                                                                                    In all cases, optimum control of intraocular inflammation was achieved by the time IVB was initiated

  Kim (2009)[@R32]                 Before--after study of IVB group and triamcinolone acetonide group (retrospective)   MO due to BRVO (56.9)                                                      50 (50) (22 received IVB and 28 received triamcinolone acetonide)   NA                                                        1.25 mg single dose                                                                                                                                     NR                                                                      24 weeks                                                   NR                                          NR                                                                                                                                    NR

  Kim (2011)[@R65]                 Case series (retrospective)                                                          DMO                                                                        48 (65)                                                             Yes                                                       1.25 mg                                                                                                                                                 NR                                                                      ≥12 months                                                 NR                                          Grant from Kyung Hee University                                                                                                       

  Kim (2011)[@R29]                 Non-randomised controlled study (prospective, consecutive)                           AMD, RVO, DMO (64.8)                                                       60 (60)                                                             Yes                                                       1.25 mg                                                                                                                                                 1                                                                       NR                                                         NR                                          NR                                                                                                                                    

  Kiss (2006)[@R66]                case-control (retrospective)§§                                                       AMD (NR)                                                                   61                                                                  Yes                                                       1 mg                                                                                                                                                    1                                                                       7 days                                                     Local dispensing service                    NR                                                                                                                                    

  Krebs (2009)[@R67]               Case series (prospective)                                                            AMD (NR)                                                                   44 (44)                                                             Unknown                                                   1.25 mg 3 monthly injections based on OCT and FA findings                                                                                               2.6                                                                     1 week, 1 month and 3 months                               NR                                          L. Boltzmann Institute\                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        \                                                                                                                                     

  Kriechbaum (2008)[@R68]          Case series (prospective)                                                            MO due to BRVO or CRVO (66)                                                28 (29)                                                             Unknown                                                   1 mg at 4-week intervals 3 intravitreal injections                                                                                                      5.3                                                                     1, 7 and 28 months                                         Local dispensing service                    NR                                                                                                                                    

  Krishnan (2009)[@R69]            Case control (retrospective) ¶¶                                                      CNV due to AMD (80.5)                                                      14                                                                  No                                                        1.25 mg                                                                                                                                                 NR                                                                      2 and 4 weeks                                              NR                                          NR                                                                                                                                    

  Kumar (2012)[@R70]               Case series (retrospective)                                                          Eales' disease (median, 33)                                                14 (14)                                                             Unknown                                                   1.25 mg                                                                                                                                                 1                                                                       3 months                                                   NR                                          NR                                                                                                                                    

  Lazic (2007)[@R71]               Case series (prospective)                                                            CNV secondary to AMD                                                       102 (102)                                                           NA                                                        1.25 mg, once then as needed                                                                                                                            NR                                                                      ≥1.5 months                                                NR                                          None                                                                                                                                  Follow-up was 6-weekly and ongoing

  Lima (2009)[@R72]                Retrospective cohort study                                                           Various, mostly AMD                                                         326 (IVB injections)                                               NR                                                        NR                                                                                                                                                      NR                                                                      NR                                                         NR                                          Macula Foundation Inc.                                                                                                                Same-day bilateral injections

  Lommatzsch (2009)[@R73]          Case series (retrospective)                                                          AMD (77.7)                                                                 86                                                                  NR                                                        1.25 mg at 6 week intervals                                                                                                                             NR                                                                      42.4 weeks                                                 NR                                          NR                                                                                                                                    

  Lorenz (2010)[@R74]              Case series (retrospective)                                                          Various\*\*\*                                                              144 (145)                                                           Yes                                                       1.25 mg                                                                                                                                                 1.63                                                                    14                                                         local dispensing service                    None                                                                                                                                  

  Mason (2008)[@R75]               Case series (retrospective)                                                          Various†††                                                                 NR                                                                  NR                                                        1.25 mg                                                                                                                                                 NR                                                                      NR                                                         NR                                          University research grant, New York.                                                                                                  

  Manayath (2009)[@R76]            Case series (prospective)                                                            CMO due to CRVO\                                                           15                                                                  No                                                        1.25 mg                                                                                                                                                 2.2                                                                     6-18 months                                                NR                                          NR                                                                                                                                    
                                                                                                                        15 (64)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Rasier (2009)[@R77]              Quasi-experimental ‡‡‡                                                               AMD (67.2)                                                                 82                                                                  Unknown                                                   1.25 mg                                                                                                                                                 1                                                                       6 weeks                                                    NR                                          NR                                                                                                                                    

  Russo (2009)[@R78]               Non-randomised controlled trial                                                      MO due to BRVO                                                             15 (15)                                                             Yes (IVB:LGP)                                             1.25 mg, once or repeated as necessary                                                                                                                  NR                                                                      12 months                                                  NR                                          NR                                                                                                                                    No. of eyes/patients refers to IVB group

  Saeed (2011)[@R79]               Cohort (prospective)                                                                 Retinal vascular occlusions and other causes of CMO (68.6)                 18                                                                  NA                                                        1.25 mg                                                                                                                                                 NR                                                                      NR                                                         NR                                          NR                                                                                                                                    Authors reported that nti-VEGF related reflux was not associated with a sub-therapeutic effect

  Shah (2011)[@R80]                Cohort (retrospective)                                                               Various                                                                    10 958 (IVB injections)                                             NR                                                        NR                                                                                                                                                      NR                                                                      6 days                                                     NR                                          NR                                                                                                                                    

  Sharma (2012)[@R81]              Cohort (retrospective)                                                               AMD, DMO RVO (IVB group,76.9)                                              173 (693 IVB injections)                                            No difference in age and VA (IVB:IVR)                     1 mg                                                                                                                                                    unclear                                                                 NR                                                         Local dispensing service                    Part-funded by Novartis (and part-funded by Canadian Institutes for Health Research)                                                  IVR patients were on average 1.8 years\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              older than IVB patients (78.7 vs 76.9, p\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              0.01) and had slightly worse baseline vision (6/76\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              vs 6/64, p 0.013). 195 out of the 351 patients that received IVR, had been treated previously with IVB (mean, 4.3 injections per patient). Prior treatment in IVB group unclear

  Shienbaum (2012)[@R82]           Case series (retrospective)                                                          AMD                                                                        73 (74)                                                             Yes (IVB:IVR)                                             NR (Monthly treatment until no intraretinal or subretinal fluid on optical coherence tomography. Treatment intervals determined by signs of exudation   NR                                                                      1.41 years                                                 NR                                          None reported                                                                                                                         

  Shima (2008)[@R83]               Case series (retrospective)                                                          Various§§§                                                                 707 (1300 injections)                                               NR                                                        1 mg\                                                                                                                                                   NR                                                                      ≥2 months                                                  NR                                          Health\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                 Once or repeated injections                                                                                                                                                                                                                                                                                                            Sciences Research Grant, Ministry of Health, Labour and Welfare, Japan                                                                

  Shimada (2011)[@R84]             Case series (retrospective)                                                          Myopic CNV (58.4)                                                          74 (74)                                                             NA                                                        1.25 mg\                                                                                                                                                NR                                                                      12 months (SD-4.3)                                         NR                                          Grants 19390441 and 19659445 from the Japan Society for the Promotion of Science, Tokyo, Japan                                        
                                                                                                                                                                                                                                                                                                                                 At baseline, week 1, then monthly (unspecified length of time)                                                                                                                                                                                                                                                                                                                                                                                                               

  Sivkova (2010)[@R85]             case series (prospective)                                                            CME due to DR, BRVO and CRVO (DR patients 59.7;\                           96 (107)                                                            Unclear (DR:RVO)                                          1.25 mg 3 consecutive injections at 1-monthly intervals                                                                                                 NR                                                                      4 months                                                   NR                                          NR                                                                                                                                    No significant difference in adverse events between groups
                                                                                                                        RVO patients, 68)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Sohn (2011)[@R86]                Case control (prospective) ¶¶¶                                                       DMO (54.5)                                                                 11                                                                  NA                                                        1.25 mg                                                                                                                                                 NR                                                                      1.3 months                                                 NR                                          GachonUniveristy, Incheon Korea                                                                                                       

  Song (2011)[@R87]                Case control (retrospective)\*\*\*\*                                                 DMO (57.1)                                                                 35 (58)                                                             Yes (IVB:IVT)                                             1.25 mg                                                                                                                                                 NR                                                                      8 weeks                                                    NR                                          Institute for Medicine research grant of Kosin University College of Medicine                                                         

  Sonmez (2011)[@R88]              Case series (prospective)                                                            Subfoveal CMO due to AMD (69.4)                                            24 (24)                                                             NA                                                        1.25 mg weeks 0, 6 and 12, then every 12 weeks until week 48                                                                                            5                                                                       NR                                                         NR                                          NR                                                                                                                                    Of 27 patients, 3 were lost to follow-up/protocol violation)

  Spandau (2006)[@R89]             Case series (retrospective, consecutive)                                             AMD                                                                        63                                                                  NA                                                        1.5 mg                                                                                                                                                  NR                                                                      ≥2 months                                                  NR                                          NR                                                                                                                                    

  Torres-Soriano (2012)[@R90]      Case series (prospective)                                                            CNV PDR, RVO (NR)                                                          31                                                                  NA                                                        2.5 mg, frequency not reported                                                                                                                          1.3                                                                     1 month                                                    NR                                          NR                                                                                                                                    

  Valmaggia (2009)[@R91]           Case series (retrospective)                                                          CNV due to AMD (75.5)                                                      324                                                                 NA                                                        1.25 mg; then every 6 weeks. Frequency not reported                                                                                                     3.3                                                                     NR                                                         Local pharmacy                              NR                                                                                                                                    

  Weinberger (2007)[@R92]          Case series (retrospective)                                                          PED in exudative AMD (76)                                                  31 (31)                                                             NA                                                        1.25 mg once                                                                                                                                            NR                                                                      1--7 months                                                NR                                          Academic institution                                                                                                                  

  Wickremasinghe (2008)[@R93]      Case series (retrospective)                                                          Neovascular AMD                                                            1278 IVB injections                                                 NA                                                        1.25 mg                                                                                                                                                 NR                                                                      1 week                                                     NR                                          NR                                                                                                                                    

  Wu (2008)[@R94]                  interventional case series (prospective)                                             Various (including RVO, DMO)                                               1173 (1310)                                                         NA                                                         1.25 mg (16%), 2.5 mg (89%)                                                                                                                            3.7 (3.3 per eye)                                                       12--15 (13.6)                                              NR                                          No                                                                                                                                    

  Yoon (2012)[@R95]                Case series (retrospective)                                                          Myopic CNV (49)                                                            26                                                                  NA                                                        1.25 mg                                                                                                                                                 2.2                                                                     12 months                                                  NR                                          NR                                                                                                                                    Of the 40 patients included in the study, 14 received IVR

  Zhang (2012)[@R96]               Non-randomised interventional case series (prospective)                              Subfoveal idiopathic CNV (32)                                              40                                                                  NA                                                        1.25 mg                                                                                                                                                 2                                                                       12 months                                                  NR                                          NR                                                                                                                                    
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

This table summarises the study characteristics of included observational studies.Data shown here include patient charateristics, interventions and outcomes reported in the included studies.

\*Artunay 2009[@R35] studied patients with the following conditions: AMD, CNV due to myopic degeneration idiopathic and other secondary causes, cystoid or diffuse MO from CRVO, BRVO, diabetes, uveitis and retinitis pigmentosa proliferative retinopathies.

†Population included patients CNV due to AMD, DMO, DR, MO due to RVO or autoimmune retinopathy.

‡Forty-seven patients out of a study population of 71 received bevacizumab. A number of patients received all three anti-VEGF medications while others received just one treatment type. However, authors reported that only the first anti-VEGF injection was considered in the study.

§Gamulescu (2010)[@R51] included a control group that received ranibizumab.

¶Re-injection in five eyes, 1 or 2 months after first injection at physician discretion.

\*\*Good *et al*[@R31] included a control group that received ranibizumab.

††101 eyes received bevacizumab only, 96 eyes received ranibizumab only and 18 eyes received bevacizumab and ranibizumab.

‡‡Population included patients AMD, diabetes, retinal vein occlusion and other eye conditions.

§§Kiss *et al*[@R66] included a control group that received triamcinolone acetonide.

¶¶Krishnan *et al*[@R69] included a control group that received ranibizumab.

\*\*\*Population included patients with AMD, BRVO, CRVO and myopic choroidal neovascularisation.

†††Population included patients with neovascular AMD; BRVO, CRVO; cystoid macular oedema; proliferative DR and DMO.

‡‡‡Rasier *et al*[@R77] reported between-group comparison of hypertensive/non-hypertensive patients.

§§§Conditions included AMD, DR, CNV, BRVO, CRVO and other pathologies (unspecified).

¶¶¶Control group received triamcinolone acetonide.

\*\*\*\*Control group received triamcinolone acetonide.

AMD, age-related macular degeneration; BP, blood pressure; BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; CMO, cystoid macular oedema; CNV, choroidal neovascularisation; DMO, diabetic macular oedema; DR, diabetic retinopathy; FA, fluorescein angiography; IVB, intravitreal bevacizumab; IVP, intravitreal pegaptinib; IVR, intravitreal ranibizumab; MO, macular oedema; NA, not applicable, NR, not reported; OCT, optical coherence tomography; PDT, photodynamic therapy; RVO, retinal vein occlusion; PED, pigment epithelium detachment.

Treatment schedule and source {#s3b}
-----------------------------

Administration of 1.25 mg/0.05 mL was the most commonly reported dosage of IVB. Frequency of dosing and follow-up schedules varied across studies. Information relating to the source of IVB was reported in 35% (n=14/22) of RCTs but less than a fifth (19%; n=13/67) of observational studies.[@R28] [@R42] [@R47] [@R48] [@R59] [@R62] [@R66] [@R68] [@R74] [@R81] [@R91] IVB was mostly provided by a local dispensing service such as the hospital\'s pharmacy. There were limited data to assess quality of administered IVB.

Reporting of AEs {#s3c}
----------------

Ascertainment of AEs was presented more objectively in RCTs compared to observational studies. Non-RCT evidence was unclear because several studies reported absence of events as 'no serious complications'; or 'no ocular complications', or 'no adverse events were observed', thereby providing limited information on diagnostic techniques or criteria for reported AEs. Furthermore, for AEs such as visual loss, ocular haemorrhage, hypertension and hospitalisation, the relationship between the outcomes and treatment schedule or setting remained largely unclear.

### AEs reported in RCTs {#s3c1}

Pooled 1-year data[@R16] [@R19] indicated that the risk of death (RR 1.38; 95% CI 0.71 to 2.68) or arteriothrombotic events (RR 0.81; 95% CI 0.42 to 1.59) were not significantly different between patients with AMD who received IVB or intravitreal ranibizumab (IVR). Furthermore, no significant difference in death between the IVB and IVR arms was observed when the CATT[@R16] (2 year data) and IVAN[@R19] (1 year preliminary data) clinical trials were pooled to provide long-term data analyses as shown in [figure 2](#BMJOPEN2014005244F2){ref-type="fig"}. Cardiac disorders, transient ischaemic attack and hospitalisation for angina were not significantly different between patients with AMD treated with IVB and IVR.[@R19] However, serious systemic AE rates remained significantly lower in the IVR group (n=1795, RR 1.27 CI 1.09 to 1.47).

![Pooled analysis of systemic adverse events comparing intravitreal bevacizumab with intravitreal ranibizumab in patients with age-related macular degeneration. This figure shows the pooled effect estimate for systemic adverse events comparing intravitreal bevacizumab with intravitreal ranibizumab in patients with age-related macular degeneration. IVB, intravitreal bevacizumab; IVR, intravitreal ranibizumab. This figure has been reproduced from the full report related to this project available at http://www.nicedsu.org.uk/Bevacizumab%20report%20%20NICE%20published%20version%2011.04.13.pdf.](bmjopen2014005244f02){#BMJOPEN2014005244F2}

Two smaller studies, Biswas *et al*[@R15]and Gharbiya *et al*,[@R18] with safety data for patients with AMD reported no significant AEs. No significant differences were found for death and myocardial infarction (MI) in studies that compared IVB to pegaptinib[@R26]or sham injection[@R7] (n=232 patients, RR 0.30; 95% CI 0.01 to 7.18).

Rates for endophthalmitis were not significantly different between IVB and IVR treatment groups for patients with AMD (1 RCT; RR 1.79; 95% CI 0.53 to 6.08).[@R16] There were no reports of endophthalmitis,[@R9] [@R11] ocular hypertension,[@R9] [@R11] retinal detachment[@R2] [@R9] or vitreous haemorrhage[@R9] [@R11] in treatment groups comparing IVB with laser therapy in patients with DMO (n=269). In patients with DMO,[@R21] [@R22] [@R25] ocular hypertension (IOP\>21 mm Hg) was significantly higher in the IVT group (n=183; RR 0.13; CI 0.02 to 0.69) compared with the IVB group. A similar but non-significant trend was demonstrated in patients with RVO (n=32 patients; RR 0.08; CI 0.00 to 1.25).[@R17]

One short-term study at 3 months[@R20] showed that posterior vitreous detachment was significantly higher in the IVB group compared with laser therapy (n=110; RR 17.00; CI 1.01 to 287.50). However, the rates of uveitis, vitreous haemorrhage, pigment epithelial tears and cataract progression were low and indicated no significant differences between IVB and laser therapy. No significant differences in rates of foveal haemorrhage[@R13] (n=81; RR 0.62; 95% CI 0.28 to 1.35) or hyphema[@R27] (n=26; RR 7.8; 95% CI 0.46 to 131.62) were found in patients with RVO who had IVB or sham injection.

### AEs reported in observational studies {#s3c2}

[Table 3](#BMJOPEN2014005244TB3){ref-type="table"}, summarising safety data reported in observational studies, displays extensive variation in the detail of reporting of AEs with most studies not reporting or observing AEs of interest. While high event rates were reported for hospitalisation, hypertension, anterior chamber reaction and visual loss, these rates need to be interpreted with caution due to previously mentioned issues with reporting along with likely confounders.

###### 

Serious systemic and ocular adverse events reported in included observational studies

  Systemic adverse events                               
  ---------------------------- -------------- --------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Death                        0.4 to 3.8     6\*       Not applicable
  Hospitalisation              32†            1         Not applicable
  Non-ocular haemorrhage       0.0            1         100%(n=1)[@R82]
  Arterial thromboembolism     0.0 to 1.35‡   9         78% (n=7)[@R34] [@R38] [@R44] [@R82] [@R85] [@R88] [@R96]
  Hypertension                 0.0 to 15.6    9         44% (n=4)[@R42] [@R43] [@R82] [@R96]
  Myocardial infarction        0.0 to 8.2     10        50% (n=5)[@R34] [@R38] [@R56] [@R67] [@R82]
  Cerebrovascular accident     0.0 to 8.7     11§       45% (n=5)[@R34] [@R38] [@R56] [@R67] [@R82]
  Transient ischaemic attack   0.4 to 1.0     5[@R34]   60% (n=3)[@R34] [@R67] [@R82]
  Ocular adverse events                                 
  Infectious endophthalmitis   0.0 to 1.0     31¶       62% (n=19)[@R29] [@R32] [@R41] [@R43] [@R44] [@R51] [@R56] [@R59] [@R60] [@R65] [@R67] [@R73] [@R76] [@R81] [@R85] [@R86] [@R88] [@R91] [@R96]
  Retinal detachment           0.0 to 29.0    20        75% (n=15)[@R29] [@R32] [@R35] [@R56] [@R65] [@R67] [@R68] [@R76] [@R79] [@R81] [@R85] [@R86] [@R91] [@R95] [@R96]
  Retinal tear                 0.0 to 15.0    14        42% (n=6)[@R29] [@R44] [@R52] [@R60] [@R65] [@R85]
  Anterior chamber reaction    0.0 to 50.0    21\*\*    57% (n=12)[@R29] [@R41] [@R43] [@R44] [@R51] [@R56] [@R67] [@R68] [@R85] [@R88] [@R91] [@R96]
  Ocular haemorrhage           0.0 to 72.0    14        43% (n=6)[@R32] [@R41] [@R52] [@R56] [@R85] [@R91]
  Lens damage                  0.0 to 0.5     9         67% (n=6)[@R41] [@R56] [@R65] [@R67] [@R85] [@R91]
  Ocular hypertension          0.0 to 20.0    16††      50% (n=8)[@R29] [@R32] [@R36] [@R41] [@R65] [@R70] [@R87] [@R91]
  Visual loss                  0.0 to 50.0    9         11% (n=1)[@R85]

Estimates of adverse event incidence were calculated by dividing the number of reported events by the number of patients that received IVB (event rate per patient) or the number of eyes treated (event rate per treated eye).

\*One study presented an HR of 1.11 (99% CI 1.01 to 1.23, IVB vs IVR).

†Incidence of systemic adverse events was reported based on number of injections and not patients, 32% (n=222/693 injections).

‡Event rate was presented for a sub-group to the study population living in a specified geographical area.

§ One study reported an HR of 1.57 (99% CI 1.04 to 2.37, IVB vs IVR).

¶Authors of one study stated that the rate of infectious endophthalmitis after an IVB injection of 1.5 mg may be approximately 1:1000.

\*\*One study reported an HR of 1.8 (99% CI 1.2 to 2.8, IVB vs IVR).

††One study reported an HR of 0.81 (99% CI 0.71 to 0.93, IVB vs IVR).

Systemic AEs reported included death (0.4--3.8%),[@R40] [@R48] [@R54] [@R94] arterial thromboembolism (0--1.4%),[@R81] hypertension (0--15.6%),[@R67] [@R77] [@R83] [@R94] MI (0--8.2%),[@R28] [@R45] [@R81] [@R94] cerebrovascular accident (0--8.7%)[@R39] [@R45] [@R54] [@R83] [@R94] and transient ischaemic attack (TIA) (0.4--1.0%).[@R40] [@R81]

Visual loss was the most commonly reported ocular event,[@R28] [@R32] [@R35] [@R50] [@R53] [@R56] [@R69] [@R89] the definition of visual loss was often unclear and occasionally associated with AEs such as anterior chamber inflammation, severe intraocular inflammation or retinal detachment. Consequently, it is uncertain whether visual loss occurred as an AE from treatment or progression of the patient\'s condition. Infectious endophthalmitis was reported in 10 studies (range 0--1.0%). Three of the 13 studies[@R28] [@R42] [@R47] [@R48] [@R59] [@R62] [@R66] [@R68] [@R74] [@R81] [@R91] in which patients received locally prepared IVB reported cases of infectious endophthalmitis. Reported rates were 0.02% (n=3/12 585 injections),[@R47] 0.2% (n=1/625)[@R62]and 0.8% (n=1/112).[@R42] A higher rate of 0.9% (n=1/109) was reported in a study with IVB supplied by a compounding pharmacy.[@R48] Positive cultures of microorganisms were reported in a study from Fong *et al*,[@R48] and another study from Wu *et al*.[@R94]

Discussion {#s4}
==========

Eighty-nine studies were included in this systematic review of AEs, 22 of which were RCTs. Trials compared IVB with a number of different therapies and eye conditions, though most were in AMD, DMO and RVO. Most ocular and systemic safety measures had zero events in treatment groups or were not significantly different between groups. The quality of reporting of studies made it impossible to evaluate the impact of both known and unknown confounding factors (eg, the use of prophylactic antibiotic eye drops) on the incidence of AEs.

The most robust data for safety are from the CATT[@R16] and IVAN[@R19] trials which were large trials that reported longer term data. The results of these trials when meta-analysed revealed a statistically significantly higher rate of 1 or more serious systematic AE (RR 1.27; 95% CI 1.09 to 1.47) in the IVB group. In this analysis, the IVAN study[@R19] alone did not show a statistically significant difference while event rates were higher in the CATT. The recently published 2-year results of the IVAN study, which was not included in this review, has reported relatively worse safety outcomes for patients on discontinuous treatment compared to continuous treatment.[@R97] In addition, there were no observed differences in mortality, frequency of thrombotic events or hospitalisation due to cardiac failure between groups of patients treated with IVB or IVR. Reported pooled analysis of the 2 years results of the CATT and IVAN studies tends to demonstrate that IVB and IVR are comparable in terms of safety. It is also important to note that AEs were more common in those patients who received discontinuous rather than patients on continuous treatment, that is, those with lower exposure to the drug experienced higher AE rates. An explanation for this observation is the possible role of immunological processes in drug interactions.[@R97] It is also important to note that the CATT study demonstrated some imbalances at baseline between randomised patients which may need further exploration. More patients randomised to IVB had had a previous TIA compared to those in the IVR arms. Similarly, more IVB patients had a history of MI.[@R16] Despite these caveats, these trial designs offer the most robust assessment of AEs to date.

Overall, the evidence on IVB safety from observational studies was uncertain. This has previously been reported elsewhere.[@R4] [@R5] Included studies were frequently associated with methodological weaknesses that limited the validity of the reported findings. The majority of studies were retrospective in design with small study samples or inadequate follow-up periods (less than 6 months). With respect to larger studies, observational data from Curtis *et al*.[@R45] suggest no difference in the risk of AEs between IVB and IVR once socioeconomic confounders are accounted for. On the other hand, results of an unpublished study of Medicare patients funded by Genentech[@R54] found an increased risk of stroke and death in IVB patients. The available abstract, however, did not provide sufficient information to allow an in-depth analysis of the results of this study. A recently published population-based, nested case-control study reported by Campbell *et al*[@R98] (n=91 378) found no relationship between the risk of MI, venous thromboembolism, stroke or congestive heart failure and the administration of IVR or IVB. While the risk of systemic AEs was similar for both treatment groups, there was an increased risk of acute MI for a subgroup of patients with diabetes who received IVB.

This review highlighted the challenges of assessing the safety of IVB especially due to limited opportunities for in-depth detailed analyses of the relationship between IVB preparation and reported rates of infectious endophthalmitis. In the past, case reports have suggested contaminated batches of IVB as the primary source of infection; a published review of patient safety information held by the National Patient Safety Agency in England and Wales[@R99] reported an increased risk of serious AEs including endophthalmitis following IVB treatment. The authors acknowledged that identifying the source of infection (ie, contaminated injection procedure or infected anti-VEGF) could be complex. However, Jonas *et al*,[@R63] reporting on AE rates in a study population which included patients who had received IVB and IVT, suggested that event rates were statistically independent of drug injected (p=0.45), operating surgeon (p=0.18) and patient\'s age (p=0.87).

It is also important to highlight limitations of this review. By relying on the previous systematic review[@R5] as a source of evidence, it is possible that studies that were not identified in that review may have been missed in this review. Our searches were undertaken up to 2012. An updated electronic literature search was conducted up to 23 May 2014, retrieving a total of 1300 records. A preliminary shift of titles resulted in 333 potentially relevant abstracts for further detailed examination. We would prefer to have undertaken a full update. Unfortunately, this is not possible for us at present due to lack of the extensive time and resources required. Although comprehensive and up-to-date systematic reviews are desirable, a recent analysis of a sample of systematic reviews showed that the median duration of survival indicating a requirement for an update was 5.5 years (95% CI 4.36 to7.67) in systematic reviews of randomised trials of procedures or conventional drugs.[@R100] Furthermore, many RCTs randomised small numbers of participants and these may have been underpowered to detect differences in AEs.[@R4] [@R97] Generalisability of findings may also be limited due to differences between study participants and patients seen in routine practice. In addition, there were concerns relating to ascertainment of exposure particularly in observational studies.[@R98] The influence of excluding non-English publications in this review is unclear. Additionally, adopting a narrow focus in the definition of AEs implies that data on less serious or rare events were not presented.

Conclusions {#s5}
===========

Overall, rates of serious AEs following IVB were low when compared to other intravitreal treatments, sham injection and laser therapy with relatively higher rates being reported in head-to-head studies of IVB versus ranibizumab. Most outcomes were, however, not significantly different between treatment groups. Current evidence from observational data still remains limited due to relatively small sample sizes, unclear definition, evaluation and reporting of safety outcomes as well as adequate follow-up periods. However, an opportunity to explore the relationship between the incidence of AEs and other variables such as injection techniques, pre-existing risk factors (eg, immunosuppression, cross-contamination) and quality of IVB could offer cost-saving options in providing treatment for certain ophthalmic conditions.

Supplementary Material
======================

###### Author\'s manuscript

###### Reviewer comments

We would like to thank Jennifer Dunn for administrative support throughout the project.

**Contributors:** EP coordinated the systematic review and was responsible for the conception and design, acquisition of data, analysis and interpretation of data and drafting and revision of the final manuscript. JR was responsible for the conception and design, acquisition of data, analysis and interpretation of data and drafting and revision of the final manuscript. RW was responsible for the developing and undertaking the electronic literature searches and drafting and revision of the final manuscript. EE-H and ME were responsible for acquisition of data, analysis and interpretation of data and drafting and revision of the final manuscript. AP contributed to the conception and design of the study, assisted with data collection analysis, interpretation of data and drafting and revision of the final manuscript. AW contributed to the conception and design of the study, assisted with analysis and interpretation of data and drafting and revision of the final manuscript.

**Funding:**  This manuscript is based on a report which was funded by the National Institute for Health and Care Excellence ('NICE') through its Decision Support Unit.

**Competing interests:** None.

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** Extra data relating to references of excluded full-text articles is available by emailing Edith Poku (e.poku\@sheffield.ac.uk).
